SCHEMBL6441741

SCHEMBL6441741

COC(=O)c1sc2nc(N)nc(-c3ccccc3)c2c1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.67
KDM4E B2RXH2 6/20 0.67
MAPT P10636 4/20 0.64
L3MBTL1 Q9Y468 3/20 0.64
MAPK1 P28482 2/20 0.64
TDP1 Q9NUW8 1/20 0.64
GAA P10253 1/20 0.50
BRAF P15056 1/20 0.50
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
POLB P06746 1/20 0.48
LHCGR P22888 1/20 0.48
LIMK1 P53667 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321340 0.87 KDM4E (0.67) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL6216808 0.86 LHCGR (0.64) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL27663684 0.85 MAPT (0.63) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL3320601 0.77 IKBKB (0.54) ALDH1A1KDM4EMAPTBRAFPDE4A
SCHEMBL6220766 0.77 ALDH1A1 (0.64) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL6215323 0.76 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL14281663 0.76 LHCGR (0.59) ALDH1A1KDM4EMAPTBRAFPDE4A
SCHEMBL4909475 0.76 BRAF (0.70) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL27490181 0.76 MAPT (0.61) ALDH1A1KDM4EMAPTL3MBTL1MAPK1
SCHEMBL6216358 0.75 LHCGR (0.63) ALDH1A1KDM4EMAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885KDM4E 3250/4885MAPT 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.